pyrimidine has been researched along with Huntington Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beconi, MG; Beresford, A; Brookfield, FA; Brown, CJ; Cardaun, I; Courtney, SM; Dijkman, U; Dominguez, C; Friley, WW; Hamelin-Flegg, E; Johnson, PD; Kempf, V; Lyons, K; Matthews, K; Mitchell, WL; Mrzljak, L; Munoz-Sanjuan, I; O'Connell, C; Pena, P; Powell, K; Prime, ME; Rassoulpour, A; Reed, L; Reindl, W; Selvaratnam, S; Toledo-Sherman, LM; Weddell, DA; Went, NE; Wheelan, P; Winkler, C; Winkler, D; Wityak, J; Yarnold, CJ; Yates, D | 1 |
| Bai, M; Bard, J; Beconi, M; Clayton, B; Clifton, S; Conlon, MP; Deupree, S; Dominguez, C; Duffy, BC; Freeman, E; Haber, J; Hultman, M; Irigoyen, M; Ismail, J; Khmelnitsky, Y; Kiselyov, A; Kitchen, DB; Kuok, ID; Lamers, M; Leonard, P; Luche, M; Lynch, M; Lyons, K; Manning, DD; Matthews, K; McGee, KF; Mead, T; Michels, P; Muñoz-Sanjuan, I; Newell, R; Ongeri, L; Song, RH; Toledo-Sherman, L; Wang, G; Webster, J; Wheelan, P; Wilson, C; Wityak, J; Yates, D | 1 |
2 other study(ies) available for pyrimidine and Huntington Disease
| Article | Year |
|---|---|
Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntington's disease.
Topics: Animals; Cell Proliferation; CHO Cells; Cricetulus; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Huntington Disease; Kynurenine; Kynurenine 3-Monooxygenase; Mice; Models, Molecular; Molecular Structure; Pyrimidines; Rats; Structure-Activity Relationship | 2015 |
Lead optimization toward proof-of-concept tools for Huntington's disease within a 4-(1H-pyrazol-4-yl)pyrimidine class of pan-JNK inhibitors.
Topics: Animals; Blood-Brain Barrier; Chemistry Techniques, Synthetic; Crystallography, X-Ray; Cytochrome P-450 Enzyme Inhibitors; Disease Models, Animal; Dogs; Drug Evaluation, Preclinical; Half-Life; Humans; Huntington Disease; Inhibitory Concentration 50; Madin Darby Canine Kidney Cells; Mice; Microsomes, Liver; Mitogen-Activated Protein Kinase 10; Molecular Structure; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Structure-Activity Relationship | 2015 |